Mostrar el registro sencillo del ítem

dc.contributor.authorAlvear-Jiménez, Alexis
dc.contributor.authorZabala Gutierrez, Irene
dc.contributor.authorShen, Yingli
dc.contributor.authorVillaverde, Gonzalo
dc.contributor.authorLozano-Chamizo, Laura
dc.contributor.authorGuardia, Pablo
dc.contributor.authorTinoco, Miguel
dc.contributor.authorGarcia-Pinel, Beatriz
dc.contributor.authorPrados, José
dc.contributor.authorMelguizo, Consolación
dc.contributor.authorLópez-Romero, Manuel
dc.contributor.authorJaque, Daniel
dc.contributor.authorFilice, Marco 
dc.contributor.authorContreras-Cáceres, Rafael
dc.date.accessioned2023-03-17T11:59:35Z
dc.date.available2023-03-17T11:59:35Z
dc.date.issued2022-01-17
dc.identifier.citationPharmaceutics. 2022 Jan 17;14(1):214es_ES
dc.identifier.issn1999-4923es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15667
dc.description.abstractAg2S nanoparticles are near-infrared (NIR) probes providing emission in a specific spectral range (~1200 nm), and superparamagnetic iron oxide nanoparticles (SPION) are colloidal systems able to respond to an external magnetic field. A disadvantage of Ag2S NPs is the attenuated luminescent properties are reduced in aqueous media and human fluids. Concerning SPION, the main drawback is the generation of undesirable clusters that reduce particle stability. Here, we fabricate biocompatible hybrid nanosystems combining Ag2S NPs and SPION by the electrospraying technique for drug delivery purposes. These nanostructures are composed of poly(lactic-co-glycolic acid) (PLGA) as the polymeric matrix in connection with both Ag2S NPs and SPIONs. Initially, we fabricate a hybrid colloidal nanosystem composed of Ag2S NPs in connection with PLGA (PLGA@Ag2S) by three different routes, showing good photoluminescent (PL) properties with relatively high average decay times. Then, we incorporate SPIONs, obtaining a PLGA polymeric matrix containing both Ag2S NPs and SPION (PLGA@Ag2S@SPION). Interestingly, in this hybrid system, the location of Ag2S NPs and SPIONs depends on the synthesis route performed during electrospraying. After a detailed characterization, we demonstrate the encapsulation and release capabilities, obtaining the kinetic release using a model chemotherapeutic drug (maslinic acid). Finally, we perform in vitro cytotoxicity assays using drug-loaded hybrid systems against several tumor cell lines.es_ES
dc.description.sponsorshipThis research was funded “Atracción de Talento” fellowship from the Comunidad de Madrid, grant number 2018-T1/IND-10736; the Universidad Complutense de Madrid, grant number UCM-Santander (CT63/19-CT64/19); the Junta de Andalucía (P18-HO-3882, P20_00540, A-CTS666-UGR20-FEDER); and Instituto de Salud Carlos III (PI19/01478-FEDER). P.G. acknowledges financial support from the Spanish government (MICIU) through the Ramon y Cajal research program (RyC2019-028414-I). M.F. thanks the Comunidad Autonoma de Madrid for research project No. 2017- T1/BIO-4992 (“Atracción de Talento” Action) cofunded by Universidad Complutense de Madrid. M.F. is grateful to Instituto de Salud Carlos III (ISCIII) for project No DTS20/00109 (AES-ISCIII). M.F. and L.L.C would also like to thank Comunidad de Madrid for the predoctoral grant IND2020/BIO-17523.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleElectrospraying as a Technique for the Controlled Synthesis of Biocompatible PLGA@Ag2S and PLGA@Ag2S@SPION Nanocarriers with Drug Release Capability.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35057109es_ES
dc.format.volume14es_ES
dc.format.number1es_ES
dc.identifier.doi10.3390/pharmaceutics14010214es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderComplutense University of Madrid (España) es_ES
dc.contributor.funderRegional Government of Andalusia (España) es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversion10.3390/pharmaceutics14010214es_ES
dc.identifier.journalPharmaceuticses_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Microscopíaes_ES
dc.repisalud.orgCNICNanobiotecnologíaes_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2018-T1/IND-10736es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CT63/19-CT64/19es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/P18-HO-3882es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/P20_00540es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI19/01478es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/IND2020/BIO-17523es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional